Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

被引:19
作者
Marme, F. [1 ]
Hanusch, C. [2 ]
Furlanetto, J. [3 ]
Morris, P. [4 ]
Link, T. [5 ]
Denkert, C. [6 ]
Fasching, P. A. [8 ]
Jackisch, C. [9 ]
Antolin, S. [10 ]
Solbach, C. [7 ,11 ]
Aftimos, P. [12 ]
Huober, J. [13 ]
Untch, M. [14 ]
Balic, M. [15 ]
Reinisch, M. [16 ]
Blohmer, J-U. [17 ]
Goncalves, A. [18 ]
Rey, J. [3 ]
Buechele, T. [3 ]
Loibl, S. [3 ]
机构
[1] Heidelberg Univ, Univ Hosp Mannheim, Med Fac Mannheim, Mannheim, Germany
[2] Red Cross Hosp Munchen, Breast Ctr, Dept Gynecol, Munich, Germany
[3] German Breast Grp GBG, Med & Res Dept, Neu Isenburg, Germany
[4] Beaumont Hosp, Oncol, Dublin, Ireland
[5] Tech Univ Dresden, Dept Gynecol & Obstet, Dresden, Germany
[6] Philipps Univ Marburg, Inst Pathol, Marburg, Germany
[7] Marburg Univ Hosp UKGM, Marburg, Germany
[8] Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Dept Gynecol & Obstet, Erlangen, Germany
[9] Sana Klinikum Offenbach, Dept Gynecol & Obstet, Offenbach, Germany
[10] Complejo Hosp Univ A Coruna, Hosp Teresa Herrera CHUAC, Med Oncol, La Coruna, Spain
[11] Univ Klinikum Frankfurt, Klin Frauenheilkunde & Geburtshilfe, Frankfurt, Germany
[12] Univ Libre Bruxelles, Inst Jules Bordet, Clin Trials Conduct Unit, Med Oncol, Brussels, Belgium
[13] Kantonsspital St Gallen, Brustzentrum, Dept Interdisziplinare Med Dienste, St Gallen, Switzerland
[14] Helios Klinikum Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany
[15] Med Univ Graz, Clin Dept Oncol, Graz, Austria
[16] Kliniken Essen Mitte, Interdisciplinary Breast Unit, Essen, Germany
[17] Charite Univ Med Berlin, Gynakol Brustzentrum, Berlin, Germany
[18] Inst Paoli Calmettes, Med Oncol, Marseille, France
关键词
D O I
10.1016/j.annonc.2022.03.074
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
580
引用
收藏
页码:S148 / S149
页数:2
相关论文
empty
未找到相关数据